The following discussion and analysis should be read in conjunction with the consolidated financial statements and notes to the consolidated financial statements filed as part of this Annual Report.
Forward-Looking Statements
The following discussion and analysis contains forward-looking statements within
the meaning of the federal securities laws. You are urged to carefully review
our description and examples of forward-looking statements included earlier in
this Annual Report immediately prior to Part I, under the heading
"Forward-Looking Statements." Forward-looking statements are subject to risk
that could cause actual results to differ materially from those expressed in the
forward-looking statements. You are urged to carefully review the disclosures we
make concerning risks and other factors that may affect our business and
operating results, including those made in Part I, Item 1A of this Annual
Report, and any of those made in our other reports filed with the
Critical Accounting Policies and Estimates
Our significant accounting policies are described in Note 2 to the consolidated financial statements included in this Annual Report. We believe that our accounting policies and estimates relating to revenue recognition, accrued expenses and stock-based compensation are the most critical.
Revenue Recognition
We recognize product revenues in accordance with Accounting Standards Codification ("ASC") 606, Revenue from Contracts with Customers (ASC 606). The provisions of ASC 606 require the following steps to determine revenue recognition: (1) Identify the contract(s) with a customer; (2) Identify the performance obligations in the contract; (3) Determine the transaction price; (4) Allocate the transaction price to the performance obligations in the contract; and (5) Recognize revenue when (or as) the entity satisfies a performance obligation.
41
In accordance with ASC 606, we recognize revenue when our performance obligation is satisfied by transferring control of the product to a customer. Per our contracts with customers, control of the product is transferred upon the conveyance of title, which occurs when the product is sold to and received by a customer. Trade accounts receivable due to us from contracts with our customers are stated separately in the balance sheet, net of various allowances as described in the Trade Accounts Receivable policy in Note 2- Summary of Significant Accounting Policies in the accompanying Financial Statements.
Product revenues consist of sales of Vyleesi in
We record product revenues net of allowances for direct and indirect fees, discounts, co-pay assistance programs, estimated chargebacks and rebates. Certain of these allowances represent estimates of the related obligations and, as such, knowledge and judgement are required when estimating the impact of these allowances on gross product sales for a reporting period. If any of our judgments made during a reporting period are not indicative or accurate estimates of our future experience, our results could be materially affected. Product sales are also subject to return rights, which have not been significant to date.
Inventories
Inventory is stated at the lower of cost or net realizable value, with cost being determined on a first-in, first-out basis. Our inventory, consisting of Vyleesi, has a shelf-life of three years from the date of manufacture.
On a quarterly basis, we review inventory levels to determine whether any obsolete, expired, or excess inventory exists. If any inventory is expected to expire prior to being sold, has a cost basis in excess of its net realizable value, is in excess of expected sales requirements as determined by internal sales forecasts, or fails to meet commercial sale specifications, the inventory is written down through a charge to operating expense. This analysis requires us to make estimates of forecasted future sales, which are inherently uncertain, and changes in demand, insurance overages, economic conditions, and other factors could have a significant impact on our forecasts and therefore the estimated net realizable value of our inventory.
Purchase Commitment Liabilities Losses on firm commitment contractual obligations are recognized based upon the terms of the respective agreement and similar factors considered for the write-down of inventory, including expected sales requirements as determined by internal sales forecasts
Accrued Expenses Third parties perform a significant portion of our development activities. We review the activities performed under all contracts each quarter and accrue expenses and the amount of any reimbursement to be received from our collaborators based upon the estimated amount of work completed. Estimating the value or stage of completion of certain services requires judgment based on available information. If we do not identify services performed for us but not billed by the service-provider, or if we underestimate or overestimate the value of services performed as of a given date, reported expenses will be understated or overstated.
Stock-Based Compensation
We expense the fair value of stock options and other equity awards granted.
Compensation costs for stock-based awards with time-based vesting are determined
using the quoted market price of our common stock on the date of grant or for
stock options, the value determined utilizing the Black-Scholes option pricing
model, and are recognized on a straight-line basis, while awards containing a
market condition are valued using multifactor
42
See Note 3 to the consolidated financial statements included in this Annual Report for a description of recent accounting pronouncements that affect us.
Results of Operations
Year Ended
Revenue - For the fiscal year ended
Cost of Products Sold - Cost of products sold was
Research and Development - Total research and development expenses, including
general research and development spending, were
Research and development expenses related to our Vyleesi, MCr programs, and
other preclinical programs were
The amounts of project spending above exclude general research and development
spending, which was
Cumulative spending from inception to
Selling, General and Administrative - Selling, general and administrative
expenses, which consist mainly of costs related to Vyleesi in addition to
compensation and related costs, were
Loss on License Termination Agreement - - On
During fiscal 2021, we recorded a loss of
Other (Expense) Income - Total other expense, net was
43
Income Taxes - For fiscal 2021 and fiscal 2020, the Company recorded no income tax benefit or expense as a result of the generation of and utilization of net operating losses that were subject to a full valuation allowance.
Effects of Inflation
We do not believe that inflation has had a material impact on our business, revenues or operating results during the periods presented.
Liquidity and Capital Resources
Since inception, we have generally incurred net operating losses, primarily related to spending on our research and development programs. We have financed our net operating losses primarily through debt and equity financings and amounts received under collaborative and license agreements.
Our product candidates are at various stages of development and will require significant further research, development and testing and some may never be successfully developed or commercialized. We may experience uncertainties, delays, difficulties and expenses commonly experienced by early-stage biopharmaceutical companies, which may include unanticipated problems and additional costs relating to:
?
the development and testing of products in animals and humans;
?
dependence on third party contractors and collaborators for part of our research and development;
?
ability to attract and retain experienced personnel;
?
product approval or clearance;
?
regulatory compliance;
?
good manufacturing practices ("GMP") compliance;
? intellectual property rights; ? product introduction; ?
marketing, sales and competition; and
?
obtaining sufficient capital.
Failure to enter into or successfully perform under collaboration agreements and obtain timely regulatory approval for our product candidates and indications would impact our ability to generate revenues and could make it more difficult to attract investment capital for funding our operations. Any of these possibilities could materially and adversely affect our operations and require us to curtail or cease certain programs.
During fiscal 2021, net cash used in operating activities was
During fiscal 2021, net cash used in investing activities consisted of
During fiscal 2021, net cash used in financing activities was
We have incurred cumulative negative cash flows from operations since our
inception, and have expended, and expect to continue to expend in the future,
substantial funds to develop the capability to market and distribute Vyleesi in
We intend to utilize existing capital resources for general corporate purposes
and working capital, including establishing marketing and distribution
capabilities for Vyleesi in
44
We believe that our existing capital resources will be adequate to fund our planned operations through at least twelve months from the date of issuance of these consolidated financial statements. We will need additional funding to complete required clinical trials for our product candidates and development programs and, if those clinical trials are successful (which we cannot predict), to complete submission of required regulatory applications to the FDA. However, the COVID-19 pandemic may negatively impact our operations, including possible effects on our financial condition, ability to access the capital markets on attractive terms or at all, liquidity, operations, suppliers, industry, and workforce. We will continue to evaluate the impact that these events could have on the operations, financial position, and the results of operations and cash flows during fiscal year 2022 and beyond.
We had a net loss for fiscal 2021 of
We expect to incur significant expenses as we continue to develop marketing and
distribution capability for Vyleesi in
Off-Balance Sheet Arrangements
None.
© Edgar Online, source